Expression of the MOZ-TIF2 oncoprotein in mice represses senescence.
AffiliationCancer Research UK Stem Cell Biology Group, CR-UK Manchester Institute, The University of Manchester, Wilmslow road, Manchester
MetadataShow full item record
AbstractThe MOZ-TIF2 translocation, which fuses monocytic leukemia zinc finger protein (MOZ) histone acetyltransferase (HAT) with the nuclear co-activator TIF2, is associated the development of acute myeloid leukemia. We recently found that in the absence of MOZ HAT activity, p16(INK4a) transcriptional levels are significantly increased, triggering an early entrance into replicative senescence. Because oncogenic fusion proteins must bypass cellular safeguard mechanisms, such as senescence and apoptosis, to induce leukemia, we hypothesized that this repressive activity of MOZ over p16(INK4a) transcription could be preserved, or even reinforced, in MOZ leukemogenic fusion proteins, such as MOZ-TIF2. We describe here that, indeed, MOZ-TIF2 silences expression of the CDKN2A locus (p16(INK4a) and p19(ARF)), inhibits the triggering of senescence, and enhances proliferation, providing conditions favorable to the development of leukemia. Furthermore, we describe that abolishing the MOZ HAT activity of the fusion protein leads to a significant increase in expression of the CDKN2A locus and the number of hematopoietic progenitors undergoing senescence. Finally, we report that inhibition of senescence by MOZ-TIF2 is associated with increased apoptosis, suggesting a role for the fusion protein in p53 apoptosis-versus-senescence balance. Our results underscore the importance of the HAT activity of MOZ, preserved in the fusion protein, for repression of CDKN2A locus transcription and the subsequent block of senescence, a necessary step for the survival of leukemic cells.
CitationExpression of the MOZ-TIF2 oncoprotein in mice represses senescence. 2016: Exp. Hematol
- MOZ-mediated repression of p16(INK) (4) (a) is critical for the self-renewal of neural and hematopoietic stem cells.
- Authors: Perez-Campo FM, Costa G, Lie-A-Ling M, Stifani S, Kouskoff V, Lacaud G
- Issue date: 2014 Jun
- MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2.
- Authors: Yin H, Glass J, Blanchard KL
- Issue date: 2007 Aug 13
- Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.
- Authors: Shima H, Yamagata K, Aikawa Y, Shino M, Koseki H, Shimada H, Kitabayashi I
- Issue date: 2014 Jan
- MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway.
- Authors: Sheikh BN, Phipson B, El-Saafin F, Vanyai HK, Downer NL, Bird MJ, Kueh AJ, May RE, Smyth GK, Voss AK, Thomas T
- Issue date: 2015 Nov 19
- MOZ fusion proteins in acute myeloid leukaemia.
- Authors: Troke PJ, Kindle KB, Collins HM, Heery DM
- Issue date: 2006